Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine.
作者信息
Harvie P, Désormeaux A, Bergeron M C, Tremblay M, Beauchamp D, Poulin L, Bergeron M G
机构信息
Centre de Recherche en Infectiologie, Centre Hospitalier de l'Université Laval, Quebec, Canada.
出版信息
Antimicrob Agents Chemother. 1996 Jan;40(1):225-9. doi: 10.1128/AAC.40.1.225.
Abstract
The pharmacokinetics and distribution in tissue of 2',3'-dideoxyinosine (ddI) encapsulated in sterically stabilized liposomes have been evaluated in rats. Most of the sterically stabilized liposomes concentrated in the spleen with a peak level at 24 h after their intravenous injection. An extended half-life in plasma was observed for sterically stabilized liposomes (14.5 h) compared with that of conventional liposomes (3.9 h). The systemic clearance of ddI incorporated in sterically stabilized liposomes was 180 times lower than that of the free drug. The levels of in vitro and in vivo protein binding on both conventional and sterically stabilized liposomes were also evaluated. Results suggest that the amount of proteins associated with liposomes might not be the only factor involved in the in vivo clearance of liposomes, as this process may also be influenced by the nature of the bound blood proteins.
摘要
相似文献
1
Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine.
Antimicrob Agents Chemother. 1996 Jan;40(1):225-9. doi: 10.1128/AAC.40.1.225.
2
Lymphoid tissues targeting of liposome-encapsulated 2',3'-dideoxyinosine.
AIDS. 1995 Jul;9(7):701-7. doi: 10.1097/00002030-199507000-00006.
3
Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2',3'-dideoxyinosine.
AIDS. 1994 Nov;8(11):1545-53. doi: 10.1097/00002030-199411000-00005.
4
Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes.
J Pharmacol Exp Ther. 2000 Mar;292(3):1071-9.
5
Pharmacokinetics of 2',3'-dideoxyinosine (BMY-40900), a new anti-human immunodeficiency virus agent, after administration of single intravenous doses to beagle dogs.
Antimicrob Agents Chemother. 1991 Apr;35(4):610-4. doi: 10.1128/AAC.35.4.610.
6
Pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and pentamidine in rats.
Pharm Res. 1996 Apr;13(4):628-32. doi: 10.1023/a:1016018726327.
7
Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics.
AIDS. 1995 Aug;9(8):833-41. doi: 10.1097/00002030-199508000-00002.
8
Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in rats.
Antimicrob Agents Chemother. 1992 Mar;36(3):665-8. doi: 10.1128/AAC.36.3.665.
9
Effect of ciprofloxacin on the disposition of 14C-dideoxyinosine-derived radioactivity in the rat.
Res Commun Chem Pathol Pharmacol. 1993 May;80(2):163-74.
10
Pharmacokinetics of dideoxyinosine in pigtailed macaques (Macaca nemestrina) after intravenous and subcutaneous administration.
J Acquir Immune Defic Syndr (1988). 1992 Oct;5(10):1016-8.
引用本文的文献
1
Lipid Nanocarriers for Anti-HIV Therapeutics: A Focus on Physicochemical Properties and Biotechnological Advances.
Pharmaceutics. 2021 Aug 19;13(8):1294. doi: 10.3390/pharmaceutics13081294.
2
An investigation of rhinovirus infection on cellular uptake of poly (glycerol-adipate) nanoparticles.
Int J Pharm. 2020 Nov 15;589:119826. doi: 10.1016/j.ijpharm.2020.119826. Epub 2020 Aug 29.
3
Pharmaceutical Approaches to HIV Treatment and Prevention.
Adv Ther (Weinh). 2018 Oct;1(6). doi: 10.1002/adtp.201800054. Epub 2018 Jul 29.
4
Nanotechnology and the treatment of HIV infection.
Viruses. 2012 Apr;4(4):488-520. doi: 10.3390/v4040488. Epub 2012 Apr 10.
5
Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases.
Eur J Clin Pharmacol. 2007 Feb;63(2):165-72. doi: 10.1007/s00228-006-0240-x. Epub 2006 Dec 19.
6
Effects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in mice.
Antimicrob Agents Chemother. 1997 Jul;41(7):1531-6. doi: 10.1128/AAC.41.7.1531.
本文引用的文献
1
Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation.
Chem Phys Lipids. 1993 Sep;64(1-3):249-62. doi: 10.1016/0009-3084(93)90069-f.
2
Liposome-complement interactions in rat serum: implications for liposome survival studies.
Biochim Biophys Acta. 1994 Apr 20;1191(1):43-51. doi: 10.1016/0005-2736(94)90231-3.
3
Long-circulating (sterically stabilized) liposomes for targeted drug delivery.
Trends Pharmacol Sci. 1994 Jul;15(7):215-20. doi: 10.1016/0165-6147(94)90314-x.
4
Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2',3'-dideoxyinosine.
AIDS. 1994 Nov;8(11):1545-53. doi: 10.1097/00002030-199411000-00005.
5
Lymphoid tissues targeting of liposome-encapsulated 2',3'-dideoxyinosine.
AIDS. 1995 Jul;9(7):701-7. doi: 10.1097/00002030-199507000-00006.
6
The involvement of parenchymal, Kupffer and endothelial liver cells in the hepatic uptake of intravenously injected liposomes. Effects of lanthanum and gadolinium salts.
Biochim Biophys Acta. 1981 Sep 18;677(1):79-89. doi: 10.1016/0304-4165(81)90148-3.
7
Differential uptake of liposomes varying in size and lipid composition by parenchymal and kupffer cells of mouse liver.
Life Sci. 1982 Nov 8;31(19):2061-71. doi: 10.1016/0024-3205(82)90098-4.
8
Fate and behavior of liposomes in vivo: a review of controlling factors.
Crit Rev Ther Drug Carrier Syst. 1987;3(2):123-93.
9
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.
Proc Natl Acad Sci U S A. 1988 Sep;85(18):6949-53. doi: 10.1073/pnas.85.18.6949.
10
The macrophage in the persistence and pathogenesis of HIV infection.
AIDS. 1989 Aug;3(8):475-95. doi: 10.1097/00002030-198908000-00001.
Zotero 插件